Page 67 - MemoriaES-Eng

www.ciberes.org

Assessment of ideas.

In 2013 the PDTT evaluated 6 ideas. For 3 of them, the PDTT led the assessment by

means of evaluating the state of the art and the market. The other 3 were led by
majority co-owning institutions. For all 6, interest was evaluated and the informa-

tion and protection procedure was managed together patent co-owners, inventors
and agents.

The following table shows the ideas at CIBERES that are currently in a protection

and/or company search phase:

CIBERES Title of the Invention
Ownership
Transfer leader
Status
Group

IGTP: 50% / CIBERES
Seeking 17 Method of genotyping
CIBERES: 50%
company
bacterial clones by IS
In
CIBERES: 66,7%
/FIB Hospital collaboration miRNA Biomarkers set for
Universitario de CIBERES
agreement 23 Diffuse Alveolar Damage
with a
Getafe: 33,3%
company

miRNA Biomarkers for
U. Lleida: 50% / IRB Lleida/ Evaluating 35 Assessment of CPAP use in
50%: CIBERES
CIBERES
market
SAOS and RH patients

CIBERES: 66,6 %
/ Sistema Canario CIBERES
Seeking VILI Early Diagnosis by 29
Salud: 33,3%
company
Microparticles.

Patent management.

Throughout 2013 up until January 2014, 4 new patents listing CIBERES as a co-ow-

ner were filed, and all the steps required for the 11 patents were taken. These steps
include: requesting and evaluating budgets, specifications, information, communi-

cation with co-owners, inventors and agents, filing patent extensions, performing
timely follow-up and filing corrections and applications in a timely manner; drafting

and managing specific agreements with inventors, and co-ownership, assignment,

non-disclosure and collaboration agreements, and closing reports....

All the current patents in which CIBERES is listed as an owner are shown in the
following table:

Date and
Priority CIBERES Transfer
Application Title of the invention group
Owners
Extensions
leader
Status

No.
Detection of
streptococcus Active.
pneumoniae through CSIC: 50% PCT/ licensed to 13
16/12/2009 magneto-amperometric 2 UCM: 26% ES2010/070836 CSIC
Alphasip 20
P200931177
genosensors using lyta CIBERES: 24%
19/12/10
date: T
gene-specific primers
OR
12/19/2012
P
and probes
RE
Use of seconeolitsine and ISCIII: 50% Spanish L
17/12/2009 n-methyl-seconeolitsine U. Valencia: 40% PCT/ patent in A
P200931186
3 for the manufacture of CSIC: 5% ES10/070808 ISCIII
force. PCT NU
medicaments
CIBERES: 5%
03/12/2010
abandoned
N
A
UB: 33,3% S /
29/07/2010 Device for generating an IDIBAPS: 13,3% Univ. de E
ES 201031183
obstruction of the upper 12 H. Clinic: 33,3% Barcelona
Abandoned
ER
airways in animals
CIBERES: 20%
B
CI
Pyrimidine urea-derived CIBERES: 50% PCT/ Spanish
28/12/2010 compound for treating 29 U.La Laguna: 25% ES2011/070822 CIBERES
patent in
P201031978
inflammatory diseases
Sistema Canario force. PCT
Salud: 25%
25/11/2011
abandoned 67